Short summary of the supply dynamics of the new ANDA approvals:
| Molecule | Launched | CY22 Market Share | Number of Indian Competitors | Market Leader | Value of Indian Exports to US (Million) 2022 | Market Leader’s Share |
|---|---|---|---|---|---|---|
| Carboprost | – | New ANDA Q4FY23 | Only Dr. Reddy’s | Dr. Reddy’s | 18.1 | 100% |
| Rocuronium Bromide | – | New ANDA Q4FY23 | 2 | Eugia Pharma | 12.2 | 73% |
| Thiamine Hydrochloride | – | New ANDA Q4FY23 | 2 | Cadila & Eugia Pharma | 1.8 | 50% |
Looking at the previous post
Carboprost and Rocoronium have the market size to become important molecules for Caplin.
It will be interesting to see how market share in Ketorolac changes in 2023, as Alembic is entering the market:
| Subscribe To Our Free Newsletter |
